{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/olecranon-bursitis/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"606247ee-02bd-5fbb-ac4e-00181cb9d573","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field b52ce39b-d23e-43ed-a28e-c4cfcf1ce994 --><h2>Changes</h2><!-- end field b52ce39b-d23e-43ed-a28e-c4cfcf1ce994 -->","summary":null,"htmlStringContent":"<!-- begin item 0deb5ba5-3006-4694-b7fc-998762e70e00 --><!-- begin field 8c7cbf52-6f51-4dbc-a8ee-11ea7120525a --><p><strong>January 2021</strong> — minor update. Contraindications and drug interactions for erythromycin have been updated in line with an MHRA drug safety update. </p><!-- end field 8c7cbf52-6f51-4dbc-a8ee-11ea7120525a --><!-- end item 0deb5ba5-3006-4694-b7fc-998762e70e00 -->","topic":{"id":"677058a2-327c-5c74-b020-fa294dc001d6","topicId":"2b5681b1-a6ac-486f-9c29-562f1d00c942","topicName":"Olecranon bursitis","slug":"olecranon-bursitis","lastRevised":"Last revised in January 2021","chapters":[{"id":"a4276506-6266-5cf4-a65d-b517b5e29073","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5f6379bf-0c3e-5f36-b626-ae14f093855a","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"30dc5fe8-8e10-5195-be9c-2032a2fe9c29","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"606247ee-02bd-5fbb-ac4e-00181cb9d573","slug":"changes","fullItemName":"Changes"},{"id":"13cfdc08-b4d8-56a4-a5ac-0dfa1d7e6cfe","slug":"update","fullItemName":"Update"}]},{"id":"3f962ec9-103d-50a6-876c-4a47fb7de1c6","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"c7da3eeb-0643-5b34-ab2c-8ba9d3db1032","slug":"goals","fullItemName":"Goals"},{"id":"ce4821e2-3cc9-5e64-a68c-2347bb4c8b71","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"d54ee925-bde2-5a23-a8d7-5890790b3298","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"55611326-78d9-5af9-a3d8-3243f894aff6","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"97a3cb4a-8ad1-5279-9a00-d3071c8afd3f","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"0ae95433-ad22-5338-aab8-270312eb6fa0","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"9d59d92b-a3ce-5a17-ad08-8bdcd5032439","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"198864d0-53c2-5b2c-b236-08be4dd0177d","slug":"definition","fullItemName":"Definition"},{"id":"1c159260-37b3-563a-831f-16da306c92e0","slug":"causes","fullItemName":"Causes"},{"id":"83714e1b-4423-54d1-893d-80c2a92a842a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e2b0682f-f14b-5991-9d25-9d0a5572ae36","slug":"prognosis","fullItemName":"Prognosis"},{"id":"a6ff79ed-b8bd-5dde-b777-048ebe2f83e8","slug":"complications","fullItemName":"Complications"}]},{"id":"f4ab30bf-b462-5a3f-bf5c-a27ae9d3e6ff","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"1d3747f8-bed3-50aa-9617-789459b5adf6","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"7ad7f12d-d8f0-59d8-8841-9ecbe656356c","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"653f7410-1fe1-5ae6-a30f-00e9b38f6285","slug":"aspiration","fullItemName":"Aspiration"}]},{"id":"33abb1c3-d06d-580c-8e89-c9f79202fcdd","fullItemName":"Management","slug":"management","subChapters":[{"id":"8eafa19f-9b61-5217-a60d-8b7150c8d22e","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"cd9798ba-7dc6-58f2-b485-1a83ce962077","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"4cc6cfee-67bb-5942-a9b4-d95ff1d2b51a","slug":"analgesia","fullItemName":"Analgesia"},{"id":"0c0460df-e8f1-55c6-9812-ab8d4105711c","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"fa9d8342-ae93-5e02-bc7e-bc3667cbfbc9","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"cdb27da7-1335-559d-9d4b-3fc3a0b6bc9b","slug":"clarithromycin","fullItemName":"Clarithromycin"}]},{"id":"004b3dea-95a9-59e3-8f0e-2c801e5ebb1a","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"06e783b5-d47f-55ea-b7be-a3cbd73f4ddb","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"1fb7925d-db93-5872-9164-840da5cf1d91","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"6a47a3d4-5551-565a-a0f6-618797e318a7","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"8a12dab5-123e-505b-bb29-69626a4ef54e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e3600086-ecd1-5ccd-9711-0f1444616612","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"87436259-d98d-5e39-ba2d-28c6133751e5","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"5c35d7b1-2c5b-5fd5-9de1-d0a85c2d7931","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"30dc5fe8-8e10-5195-be9c-2032a2fe9c29","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"18cbf3f5-9c69-5631-a44c-7ae26cbf931c","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 4f80db7c-91d5-4926-be30-53a4af6119e8 --><h3>Previous changes</h3><!-- end field 4f80db7c-91d5-4926-be30-53a4af6119e8 -->","summary":null,"htmlStringContent":"<!-- begin item bfba3458-d328-4346-890b-2a2d70b2033e --><!-- begin field a941d641-b1b7-4b1f-9d66-9bce8e3dd5bd --><p><strong>August to September 2016</strong> — reviewed. A literature search was conducted in August 2016 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. No major changes to clinical recommendations have been made, although minor restructuring of the topic has been undertaken.</p><p><strong>July 2015</strong> — minor update. The prescribing information section for clarithromycin and erythromycin has been re-written for clarity.</p><p><strong>July 2013 </strong>— minor update. Update to the text to reflect recent advice from the MHRA regarding diclofenac.</p><p><strong>February 2013 </strong>— minor update. The 2013 QIPP options for local implementation have been added to this topic.</p><p><strong>October 2012 </strong>— minor update. The 2012 QIPP options for local implementation have been added to this topic.</p><p><strong>May 2011 </strong>— minor update. The 2010/2011 QIPP options for local implementation have been added to this topic.</p><p><strong>December 2010 </strong>— minor update. Advice on use of pressure dressings after aspiration has been clarified. Issued in December 2010.</p><p><strong>November 2010 </strong>— minor update. Dose information for corticosteroid injections has now been added. Issued in November 2010.</p><p><strong>June to October 2010 </strong>— this is a new CKS topic. The evidence-base has been reviewed in detail, and recommendations are clearly justified and transparently linked to the supporting evidence.</p><!-- end field a941d641-b1b7-4b1f-9d66-9bce8e3dd5bd --><!-- end item bfba3458-d328-4346-890b-2a2d70b2033e -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}